Literature DB >> 12856080

The influence of the ACE ( I/D) polymorphism on systemic and renal vascular responses to angiotensins in normotensive, normoalbuminuric Type 1 diabetes mellitus.

P T Luik1, K Hoogenberg, M N Kerstens, B J Beusekamp, P E De Jong, R P F Dullaart, G J Navis.   

Abstract

AIM/HYPOTHESIS: The renin-angiotensin-aldosterone system is important in diabetic nephropathy, with the angiotensin-converting-enzyme DD-genotype being a renal risk factor. The D-allele is associated with higher ACE concentrations, but functional consequences in diabetes mellitus are not known. To analyse these consequences, we assessed renal and systemic responsiveness to angiotensin I infusion, with the response to angiotensin II as reference.
METHODS: Uncomplicated Type 1 (insulin-dependent) diabetic patients with contrasting genotypes (11 II and 11 DD) were studied, during low (50 mmol/24 h) and liberal (200 mmol/24 h) sodium diet, during a euglycaemic clamp. Angiotensin I was infused at 4 and 8 ng.kg(-1).min(-1), 1 h each, followed by infusions of angiotensin II after a 2-h wash-out period.
RESULTS: During low sodium, DD-homozygotes showed higher blood pressure sensitivity to angiotensin I ( DD 21+/-5% vs II 15+/-5%, p<0.01). With liberal sodium, no differences in blood pressure were detected, whereas angiotensin I induced a higher response of ERPF ( DD 40+/-5% vs II 35+/-4%, p<0.05) and RVR ( DD 105+/-20% and II 89+/-16% p<0.05) in DD-homozygotes. Differences were not explained by altered angiotensin II sensitivity. Multiple-linear regression analysis showed that angiotensin I induced responses of blood pressure and renal haemodynamics are higher in subjects carrying the DD-genotype. The magnitude of the responses was modulated by sodium intake and long-term glycaemic control. CONCLUSION/
INTERPRETATION: This study showed that responses of blood pressure and renal haemodynamics to angiotensin I are increased in diabetic subjects carrying the DD-genotype. Genotype-associated differences in ACE concentrations could, under certain circumstances, have functional consequences in uncomplicated Type 1 diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12856080     DOI: 10.1007/s00125-003-1149-x

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  42 in total

1.  Precision of glomerular filtration rate determinations for long-term slope calculations is improved by simultaneous infusion of 125I-iothalamate and 131I-hippuran.

Authors:  A J Apperloo; D de Zeeuw; A J Donker; P E de Jong
Journal:  J Am Soc Nephrol       Date:  1996-04       Impact factor: 10.121

2.  Time course of enhanced adrenal responsiveness to angiotensin on a low salt diet.

Authors:  S Rogacz; G H Williams; N K Hollenberg
Journal:  Hypertension       Date:  1990-04       Impact factor: 10.190

3.  Angiotensin converting enzyme gene polymorphism and renal artery resistance in patients with insulin dependent diabetes mellitus.

Authors:  S Fukumoto; E Ishimura; M Hosoi; T Kawagishi; T Kawamura; G Isshiki; Y Nishizawa; H Morii
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

4.  Pressor and hormonal responses to angiotensin I infusion in healthy subjects of different angiotensin-converting enzyme genotypes.

Authors:  I G Chadwick; L O'Toole; A H Morice; W W Yeo; P R Jackson; L E Ramsay
Journal:  J Cardiovasc Pharmacol       Date:  1997-04       Impact factor: 3.105

5.  Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study.

Authors:  Samy Hadjadj; Riadh Belloum; Béatrice Bouhanick; Yves Gallois; Gérard Guilloteau; Gilles Chatellier; François Alhenc-Gelas; Michel Marre
Journal:  J Am Soc Nephrol       Date:  2001-03       Impact factor: 10.121

6.  Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release.

Authors:  H O Steinberg; G Brechtel; A Johnson; N Fineberg; A D Baron
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

7.  Predicting diabetic nephropathy in insulin-dependent patients.

Authors:  C E Mogensen; C K Christensen
Journal:  N Engl J Med       Date:  1984-07-12       Impact factor: 91.245

8.  Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme.

Authors:  S Ueda; H L Elliott; J J Morton; J M Connell
Journal:  Hypertension       Date:  1995-06       Impact factor: 10.190

9.  Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man.

Authors:  N K Hollenberg; W R Chenitz; D F Adams; G H Williams
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

10.  Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects.

Authors:  M L Lachurié; M Azizi; T T Guyene; F Alhenc-Gelas; J Ménard
Journal:  Circulation       Date:  1995-06-15       Impact factor: 29.690

View more
  3 in total

1.  Rat Ace allele variation determines susceptibility to AngII-induced renal damage.

Authors:  Jelena Kamilic; Inge Hamming; A Titia Lely; Ron Korstanje; Ute Schulze; Wilfred J Poppinga; Anthony J Turner; Nicola E Clarke; Harry van Goor; Gerjan J Navis
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2011-07-25       Impact factor: 1.636

2.  ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.

Authors:  Hans-Henrik Parving; Dick de Zeeuw; Mark E Cooper; Giuseppe Remuzzi; Nancy Liu; Jared Lunceford; Shahnaz Shahinfar; Peggy H Wong; Paulette A Lyle; Peter Rossing; Barry M Brenner
Journal:  J Am Soc Nephrol       Date:  2008-01-16       Impact factor: 10.121

3.  Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine.

Authors:  Murielle Bochud; Michel Burnier; Idris Guessous
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.